Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Listen on:
Episodes
4 days ago
4 days ago
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain continue their ToxCheck series, focusing on the management of side effects associated with treatments for pancreatic cancer.
Join us as we dive deep into the use of key drugs such as 5-FU, oxaliplatin, irinotecan, liposomal irinotecan, and the combination of gemcitabine and nab-paclitaxel. We are joined by esteemed guests Dr. Rachna Shroff from the University of Arizona and Dr. Midhun Malla from the University of Alabama, who share their insights and clinical pearls on managing the challenging side effects of these therapies.
Key topics discussed include:• The utility of 5-FU bolus and leucovorin in treatment regimens• Managing common side effects like diarrhea, mucositis, and neuropathy• The importance of preemptive strategies in side effect management• Insights on liposomal irinotecan and its tolerability• The impact of gemcitabine and nab-paclitaxel on quality of life
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on optimizing treatment while maintaining patient quality of life.
YouTube: https://youtu.be/KByOGRpzFMQ
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T, and anti-EGFR drugs used in colorectal cancer.
Subscribe for more insights from the Oncology Brothers!
7 days ago
7 days ago
Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of prostate cancer with Dr. Alan Bryce, Chief Clinical Officer and GU Medical Oncologist from City of Hope.
In this episode, we explore:• The treatment paradigm for early-stage prostate cancer, including the role of active surveillance and the use of abiraterone based on the STAMPEDE trial.• The importance of understanding risk factors and treatment options for low, intermediate, and high-risk patients.• The implications of PET-PSMA imaging versus conventional CT modalities in staging and treatment decisions.• The management of biochemical recurrent disease and the significance of PSA doubling time in treatment planning.• The role of PARP inhibitors in patients with HRR mutations and the nuances of selecting appropriate therapies.• Strategies for managing metastatic disease, including the use of Lutetium-177 (Pluvicto) and cabazitaxel.
Dr. Bryce provides a masterclass on navigating the complexities of prostate cancer treatment, emphasizing the need to balance between over-treatment in early disease and under-treatment in metastatic cases.
YouTube: https://youtu.be/Zfu-yGmH0rg
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
If you find this episode helpful, please share it with your colleagues and leave us a review! Don't forget to check out our other episodes in the GU treatment algorithm series, including discussions on renal cell carcinoma and bladder cancer.
Monday Mar 17, 2025
Monday Mar 17, 2025
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology.
In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including:• The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease.• Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options.• The importance of patient characteristics and IMDC risk categorization in treatment decisions.• Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects.• The role of ctDNA, PD-L1 testing, and NGS in RCC.
Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients.
YouTube: https://youtu.be/Bbv9N7-YKIM
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!
Monday Mar 10, 2025
Monday Mar 10, 2025
Join Drs. Rahul & Rohit Gosain in this insightful episode of the Oncology Brothers podcast as they continue their treatment algorithm series, focusing on the rapidly evolving landscape of bladder cancer. They are joined by Dr. Joaquim Bellmunt, a medical oncologist and director of bladder cancer at the Dana-Farber Cancer Institute, who shares his expertise on the latest treatment paradigms for both muscle invasive and non-muscle invasive bladder cancer.
In this episode, you'll learn about:• The distinction between muscle invasive and non-muscle invasive bladder cancer and their respective treatment approaches.• The role of BCG treatment and emerging options for BCG-refractory disease.• The significance of the NIAGARA trial and its implications for neoadjuvant chemotherapy and perioperative immunotherapy.• Current strategies for managing muscle invasive bladder cancer, including the use of cisplatin-based therapies and the introduction of immunotherapy.• Insights into the metastatic space, including the use of enfortumab vedotin (EV) and pembrolizumab, and the importance of next-generation sequencing (NGS) in treatment decisions.• Key side effects to monitor with various treatments and the importance of maintaining quality of life for patients.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.
YouTube: https://youtu.be/apUp2-BkgWQ
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/ Don't forget to like, share, and subscribe for more discussions on cancer treatment algorithms!
Thursday Mar 06, 2025
Thursday Mar 06, 2025
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Anwaar Saeed, Chief of GI Medical Oncology at UPMC, to discuss the recent approval of Tislelizumab, a new checkpoint inhibitor for upper GI malignancies, including esophageal squamous cell cancer, GE junction, and gastric cancer.
We dive deep into the studies that led to Tislelizumab’s approval, including the Rationale 302, 305, and 306 trials. Dr. Saeed explains the unique mechanism of action of Tislelizumab, its higher binding affinity to PD-1, and how it compares to other PD-1 inhibitors like nivolumab and pembrolizumab.
Key topics covered in this episode:• Overview of Tislelizumab and its mechanism of action• Insights from the Rationale 306 trial and its implications for frontline treatment• Discussion on the Rationale 305 trial focusing on adenocarcinoma• The importance of PD-L1 testing and biomarker-driven treatment decisions• Side effect profiles of Tislelizumab compared to other immunotherapies• Future directions in the use of immunotherapy for upper GI malignancies
Join us for this informative discussion that highlights the evolving landscape of cancer treatment and the importance of precision oncology. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/hQeLdpSzGCk
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to subscribe for more practice-changing discussions in the world of oncology. We are the Oncology Brothers!
Monday Mar 03, 2025
Monday Mar 03, 2025
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a leading GU medical oncologist from Dana-Farber Cancer Institute. Together, they dive into the highlights from the GU ASCO 2025 conference, covering key studies and updates in the world of genitourinary oncology.
Episode Highlights:• TALAPRO-2: An in-depth discussion on the role of PARP inhibitors in prostate cancer, focusing on the study's design, findings, and the importance of germline and NGS testing.• NIAGARA Update: Insights into the new standard of care for resectable muscle-invasive bladder cancer and the promising results from the perioperative approach with Durvalumab.• CheckMate-9ER Update: A look at the combination of Cabozantinib and Nivolumab in first-line metastatic RCC, including the latest findings and implications for treatment beyond the first line.• TiNivo2: Exploring the role of Tivozanib in the treatment landscape of RCC and potential sequencing strategies.
Join us for this informative discussion that aims to keep community oncologists up to date with the latest advancements in cancer care. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/OzeHhyAdF9Q
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and updates from the Oncology Brothers!
Monday Feb 24, 2025
Monday Feb 24, 2025
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University.
Join us as we dive deep into the complexities of hormone receptor-positive breast cancer treatment. We discuss the latest advancements in treatment algorithms, including the use of OncotypeDX in premenopausal versus postmenopausal women, the role of ovarian function suppression, and the implications of new approvals like Inavolisib and CDK4-6 inhibitors.
Key topics covered in this episode:• The significance of recurrence scores in dictating adjuvant chemotherapy• The ongoing OFSET trial and its potential impact on treatment decisions• Insights into the use of genomic assays like MammaPrint and RS-Clin• The evolving landscape of treatment options for locally advanced and metastatic breast cancer• The latest on PARP inhibitors, T-DXd, and other novel therapies
Whether you're a medical professional or someone interested in the latest in oncology, this episode is packed with valuable insights and clinical pearls. Don't forget to subscribe for more discussions on cancer treatment, FDA approvals, and conference highlights!
YouTube: https://youtu.be/_icBN3J3Bc0
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
#OncologyBrothers #HR+ #breastcancer #HormoneReceptorPositiveCancer #oncbrothers #Podcast
Friday Feb 21, 2025
Friday Feb 21, 2025
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the recent advancements in the treatment of gastroesophageal junction (GEJ) and gastric cancer, focusing on the newly approved drug Zolbetuximab. They are joined by Dr. Kohei Shitara, the lead author of the pivotal SPOTLIGHT study, who shared insights on the mechanism of action of Zolbetuximab, its clinical trial findings, and the implications for patient care.
Key topics discussed include:• The mechanism of action of Zolbetuximab and its target, Claudin 18.2.• An overview of the GLOW and SPOTLIGHT studies, including study design and key findings on progression-free survival (PFS) and overall survival (OS).• Practical considerations for administering Zolbetuximab in clinical practice, including dosing schedules and side effect management.• The importance of testing for Claudin 18.2 and the challenges faced in rural settings without in-house testing.• Future directions in the treatment landscape for gastric cancer, including potential combination therapies and emerging agents.
Join us for this informative discussion that highlights the changing standard of care in gastric cancer treatment and the exciting possibilities ahead for patients.
Don't forget to like, share, and subscribe for more insightful conversations in the world of oncology!
YouTube: https://youtu.be/BfpDHpqgHMs
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
Monday Feb 17, 2025
Monday Feb 17, 2025
In this episode of the Oncology Brothers podcast, Drs. Rohit and Rahul Gosain welcome Dr. Sarah Sammons from Dana-Farber Cancer Institute to discuss the treatment landscape for HER2-positive breast cancer. Building on their previous discussions about triple-negative breast cancer, Drs. Gosain and Sammons dive deep into the treatment algorithms for early-stage, locally advanced, and metastatic HER2-positive breast cancer.
Key topics include:• Treatment paradigms for early-stage HER2-positive breast cancer, including the APT trial and considerations for neoadjuvant therapy.• The standard of care for locally advanced disease with TCHP and managing associated toxicities.• Insights into the latest data from the PATINA trial and its implications for metastatic HER2-positive patients.• Discussion on the use of T-DXd and other treatment options in the second and third-line settings, especially for patients with brain metastases.
Join us for an informative conversation filled with clinical pearls and practical insights that can help guide treatment decisions in HER2-positive breast cancer. Don't forget to like, subscribe, and check out our other episodes in the treatment algorithm series!#OncologyBrothers #HER2Positive #BreastCancer #BreastCancerTreatment #CancerPodcast #DanaFarber
YouTube: https://youtu.be/_y0xSxJTptw
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers
Monday Feb 10, 2025
Monday Feb 10, 2025
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Virginia Kaklamani from the UTHealth San Antonio MD Anderson Cancer Center to discuss the latest advances in the treatment of triple negative breast cancer (TNBC) as we kick off 2025.
• The treatment paradigms for early-stage TNBC, including the role Sacituzumab and radiation therapy.• Insights from the SABCS 2024 conference, focusing on the keynote 522 regimen and its implications for neoadjuvant treatment.• The management of locally advanced and metastatic TNBC, including the use of immunotherapy and the importance of PD-L1 testing.• Strategies for managing toxicities associated with treatments like sacituzumab and T-DXd.
Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!Key Takeaways:• Current standard of care for locally advanced TNBC.• The significance of chemotherapy and immunotherapy in treatment plans.• Managing toxicities in metastatic disease.Stay tuned for more discussions on treatment algorithms, FDA approvals, and clinical pearls in oncology!
YouTube: https://youtu.be/GfROoYPVb_8
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers